6530 |
SOLUTE CARRIER FAMILY 6 MEMBER 2 |
SLC6A2 |
NAT1 |
NET |
NET1 |
SLC6A5 |
163970 |
11048 |
ENSG00000103546 |
OTTHUMG00000133208 |
P23975 |
SC6A2_HUMAN |
926 |
BE0000486 |
PA310 |
SODIUM-DEPENDENT NORADRENALINE TRANSPORTER (NOREPINEPHRINE TRANSPORTER) (NET). [SOURCE:UNIPROT/SWISSPROT;ACC:P23975] |
SODIUM-DEPENDENT NORADRENALINE TRANSPORTER |
Norepinephrine transporter |
SLCA2 |
Human Readable Name | DRUGGABLE GENOME |
Target Subclass | Other |
Target Subclass | SLC |
Target Subclass | SLC6 |
Target Main Class | Transporters |
Transmembrane Helix Count | 12 |
Interpro Short Name | Na/ntran_symport |
Interpro Acc | IPR000175 |
Uniprot Status | Swiss-Prot |
Interpro Name | Sodium:neurotransmitter symporter |
Human Readable Name | TRANSPORTER |
Interpro Type | Family |
Uniprot Evidence | 1: Evidence at protein level |
GuideToPharmacology Gene Category Name | Monoamine transporter subfamily |
GuideToPharmacology Gene Category ID | 176 |
Target Class | Transporters |
Target Subclass | TC:2.A.22.1.2 |
Gene Biotype | PROTEIN_CODING |
TRANSPORTER |
CELL SURFACE |
DRUG RESISTANCE |
DRUGGABLE GENOME |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | sibutramine HCl monohydrate,Meridia, Reductil, Reduxade, Zelium |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | Pristiq |
Direct Interaction? | True |
inhibitor (inhibitory) |
Details of the Assay for Interaction | In a NE reuptake assay in HEK293 cells expressing hNET. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Inhibition of [<sup>3</sup>H]nisoxetine binding to CHO cells expressing hNET. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Trial Name | Cymbalta |
Novel drug target | Established target |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Trial Name | Effexor |
Novel drug target | Established target |
Specific Action of the Ligand | Inhibition |
n/a |
Novel drug target | Established target |
Trial Name | tesofensine, NS-2330 |
negative modulator (inhibitory) |
inhibitor (inhibitory) |
Novel drug target | Established target |
Trial Name | SLI 381, SPD 465,Adderall, Adderall XR, Adderall IR |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Dissociation constant of [3H]- nisoxatine <i>vs</i>. nefazodone. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Trial Name | BVF-033,Aplenzin |
Novel drug target | Established target |
Trial Name | Contrave |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
Novel drug target | Established target |
Trial Name | LY-2216684 |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Trial Name | methylphenidate HCl,Ritalin LA |
Trial Name | methylphenidate HCl,Metadate CD, Equasym |
Novel drug target | Established target |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Trial Name | - |
Novel drug target | Established target |
Specific Action of the Ligand | Inhibition |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | True |
n/a |
Trial Name | - |
Novel drug target | Established target |
inhibitor (inhibitory) |
Trial Name | fexofenadine + ps/ |
Novel drug target | Established target |
inhibitor (inhibitory) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Inhibition |
negative modulator (inhibitory) |
Trial Name | low dose intravenous methamphetamine |
Novel drug target | Established target |
antagonist (inhibitory) |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
n/a |
Trial Name | Lu AA24530 |
Novel drug target | Established target |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
inhibitor (inhibitory) |
Details of the Assay for Interaction | Inhibition of [<sup>3</sup>H]dopamine uptake at human NET expressed in COS7 cells. |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
inhibitor (inhibitory) |
Specific Action of the Ligand | Inhibition |
Endogenous Drug? | False |
Direct Interaction? | False |
SLC6A2 | Ensembl Gene Name |
Gene Biotype | PROTEIN_CODING |
SLC6A2 | Gene Symbol |
SLCA2 | Gene Symbol |
Target Class | Transporters |
Target Subclass | TC:2.A.22.1.2 |
SODIUM-DEPENDENT NORADRENALINE TRANSPORTER (NOREPINEPHRINE TRANSPORTER) (NET). [SOURCE:UNIPROT/SWISSPROT;ACC:P23975] | Description |
ENSG00000103546 | Ensembl Gene Id |
SLC6A2 | Display Id |
Human Readable Name | DRUGGABLE GENOME |
DRUGGABLE GENOME |
6530 | Entrez Gene Id |
SC6A2_HUMAN | Uniprot Id |
SLC6A2 | Uniprot Gene Name |
Interpro Short Name | Na/ntran_symport |
Human Readable Name | DRUGGABLE GENOME |
Interpro Acc | IPR000175 |
TRANSPORTER, DRUGGABLE GENOME |
6530 | Entrez Gene Id |
SLC6A2 | Gene Symbol |
P23975 | Uniprot Accession |
Target Subclass | Other |
Target Subclass | SLC |
Target Subclass | SLC6 |
11048 | HUGO Gene ID |
11048 | HUGO Gene Symbol |
solute carrier family 6 member 2 | HUGO Gene Name |
GuideToPharmacology Gene Category Name | Monoamine transporter subfamily |
GuideToPharmacology Gene Category ID | 176 |
TRANSPORTER |
PA310 | PharmGKB ID |
SLC6A2 | DrugBank Gene Name |
P23975 | UniProt Accession |
6530 | Entrez Gene Id |
ENSG00000103546 | Gene Symbol |
SLC6A2 | Ensembl Id |
DRUGGABLE GENOME |
Sodium-dependent noradrenaline transporter | Gene Name |
P23975 | UniProt ID |
TRANSPORTER |
NAT1 | GO Gene Synonym |
NET1 | GO Gene Synonym |
SLC6A5 | GO Gene Synonym |
CELL SURFACE, DRUG RESISTANCE |